EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Current Landscape of Glioblastoma Biomarkers in Body Fluids

Saba Zanganeh iD, Elham Abbasgholinejad iD, Mohammad Doroudian iD, Nazanin Esmaelizad, Fatemeh Farjadian, Soumya Rahima Benhabbour iD

Cancers · 26.07.2023 · 15 (15) · 3804

DOI: 10.3390/cancers15153804 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.07.2023. Verfasst von Saba Zanganeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 2759…. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility.

Schlagwörter

Stichwörter der Autor:innen

biomarkersbody fluidscell-free DNA (cfDNA)cell-free RNA (cfRNA)circulating tumor cells (CTCs)exosomesextracellular vesicles (EV)glioblastomamicroRNA (miRNA)

Autor:innen und Institutionen

  • Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran 15719-14911, Iran.
  • Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Saba Zanganeh, Elham Abbasgholinejad, Mohammad Doroudian, Soumya Rahima Benhabbour

Zitieren

APA

Zanganeh, S., Abbasgholinejad, E., Doroudian, M., Esmaelizad, N., Farjadian, F., & Benhabbour, S. R. (2023). The Current Landscape of Glioblastoma Biomarkers in Body Fluids. Cancers, 15(15), 3804. https://doi.org/10.3390/cancers15153804

Vancouver

Zanganeh S, Abbasgholinejad E, Doroudian M, Esmaelizad N, Farjadian F, Benhabbour SR. The Current Landscape of Glioblastoma Biomarkers in Body Fluids. Cancers. 2023;15(15):3804. doi:10.3390/cancers15153804

BibTeX
@article{Zanganeh2023,
  author = {Zanganeh, Saba and Abbasgholinejad, Elham and Doroudian, Mohammad and Esmaelizad, Nazanin and Farjadian, Fatemeh and Benhabbour, Soumya Rahima},
  title = {The Current Landscape of Glioblastoma Biomarkers in Body Fluids},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {15},
  pages = {3804},
  doi = {10.3390/cancers15153804}
}
Kostenlos starten →